Shorter-Duration Trastuzumab as Effective for HER2+ Early Breast Cancer

Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial.

Source: CancerNetwork - May 17, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news